Cargando…
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study)
This study was performed to evaluate the long-term cardiovascular safety of gemigliptin in patients with type 2 diabetes mellitus (T2DM). After screening, eligible patients with T2DM were enrolled, received gemigliptin, and were followed up for a median of 2.50 years. The primary outcome was a compo...
Autores principales: | Kim, Eun Heui, Kim, Sang Soo, Kim, Dong Jun, Choi, Young Sik, Lee, Chang Won, Ku, Bon Jeong, Cha, Kwang Soo, Song, Kee Ho, Kim, Dae Kyeong, Kim, In Joo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642439/ https://www.ncbi.nlm.nih.gov/pubmed/33149182 http://dx.doi.org/10.1038/s41598-020-75594-5 |
Ejemplares similares
-
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
por: Lee, Byung Wan, et al.
Publicado: (2023) -
Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy
por: Kim, Da Rae, et al.
Publicado: (2017) -
Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
por: Nam, Dae-Hwan, et al.
Publicado: (2019) -
Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
por: Jung, Gwon-Soo, et al.
Publicado: (2016) -
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects
por: Park, Sang-In, et al.
Publicado: (2015)